KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Common Equity (2018 - 2025)

Adaptive Biotechnologies' Common Equity history spans 8 years, with the latest figure at $218.8 million for Q4 2025.

  • For Q4 2025, Common Equity rose 7.93% year-over-year to $218.8 million; the TTM value through Dec 2025 reached $218.8 million, up 7.93%, while the annual FY2025 figure was $218.8 million, 7.93% up from the prior year.
  • Common Equity for Q4 2025 was $218.8 million at Adaptive Biotechnologies, up from $204.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $725.7 million in Q1 2021 and bottomed at $179.5 million in Q2 2025.
  • The 5-year median for Common Equity is $378.8 million (2023), against an average of $396.2 million.
  • The largest annual shift saw Common Equity soared 31.57% in 2021 before it plummeted 39.03% in 2024.
  • A 5-year view of Common Equity shows it stood at $604.1 million in 2021, then decreased by 23.18% to $464.1 million in 2022, then crashed by 33.57% to $308.3 million in 2023, then crashed by 34.24% to $202.7 million in 2024, then rose by 7.93% to $218.8 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Common Equity are $218.8 million (Q4 2025), $204.4 million (Q3 2025), and $179.5 million (Q2 2025).